GSK bets $2.1bn on Boston-based biopharma company

GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Foley Hoag adds partner in Boston

22 August 2023 Biologics patent attorney aims to strengthen the firm’s global patent networks.

Big Pharma

GSK signs licence deals with three generics firms to make HIV preventative for low income countries

30 March 2023 The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.

Big Pharma

GSK presses court to deny Teva’s ‘skinny label’ petition

25 August 2022 Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

GSK bets $2.1bn on Boston-based biopharma company

More on this story

Editor's picks

Editor's picks

More features